Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00671359 · ClinicalTrials.gov registry record · Phase 1
Food Effects of Single Oral Dose of 600mg TR-701
A Phase 1 study, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00671359 is a Phase 1 study that has completed, run by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 12 participants.
The verdict
NCT00671359, a Phase 1 study, has completed, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is an evaluation of the safety, tolerance, and pharmacokinetics of single oral doses of TR-701 given to normal, healthy, adult volunteers in the fed and fasted state.
Interventions
- DRUG TR-701 600mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-03-10 |
| Est. Completion | 2008-05-15 |
| Phase | Phase 1 |
Sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)18 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00671359
The ClinicalTrials.gov registry entry for NCT00671359 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TR-701 600mg is the first listed.
NCT00671359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00671359 about?
NCT00671359 is a clinical study titled "Food Effects of Single Oral Dose of 600mg TR-701". This is an evaluation of the safety, tolerance, and pharmacokinetics of single oral doses of TR-701 given to normal, healthy, adult volunteers in the fed and fasted state.
What is the current status of trial NCT00671359?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2008-03-10. Estimated completion is 2008-05-15.
What interventions are being tested in trial NCT00671359?
The interventions under investigation include: TR-701 600mg (DRUG).
Who is sponsoring clinical trial NCT00671359?
This trial is sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.